H.C. Wainwright analyst Yi Chen adjusted the firm’s price target for First Wave BioPharma to $18 from $4 to account for the 1-for-7 reverse stock split. The analyst keeps a Buy rating on the shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FWBI:
- FWBI Blasts Up on Expansion Potential
- First Wave BioPharma announces expansion of adrulipase IP portfolio
- First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio
- First Wave BioPharma to Present at Sequire Biotechnology Conference
- FWBI Soars on FDA Review for Adrulipase; Street Sees 5x Upside
